Perfil genĂ©tico en sĂndrome de cáncer hereditario de mama y ovario.
Autor: Yáñez FĂ©lix Ana LucĂa
BibliografĂa: HipervĂnculos 1. Vidal-Millán S. Cáncer de Mama Hereditario: IdentificaciĂłn y elecciĂłn de pacientes para estudio molecular de los genes BRCA. CancerologĂa. 2008;3:51–61. 2. Instituto Nacional de EstadĂstica y GeografĂa. EstadĂsticas a propĂłsito del dĂa mundial contra el cáncer. Datos Nacionales [Internet]. INEGI. Aguascalientes; 2017. 3. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A J Clin. 2018;00(00):1–31. 4. González-Teshima LY, Vargas-Cely FS, Muñoz-Sandoval JS, RamĂrez-Cheyne J, Saldarriaga-Gil W. SĂndrome de cáncer hereditario de mama y ovario: aplicaciĂłn clĂnica. Rev Colomb Obstet Ginecol [Internet]. 2016 Mar 31;67(1):36. 5. DeVita VT, Lawrance TS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 9na ed. Filadelfia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011. 2638 p. 6. Mutch DG, Babb SA, Disaia PJ. Genes y cáncer: consejo genĂ©tico y conducta clĂnica [Internet]. 9na ed. Clinical Gynecologic Oncology. Barcelona: Elsevier España; 2018. 7. Villarreal-Garza C, Alvarez-GĂłmez RM, PĂ©rez-Plasencia C, Herrera LA, Herzog J, Castillo D, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer [Internet]. 2015 Feb 1;121(3):372–8. 8. Kobayashi H, Ohno S, Saski Y, Matsuura M. Hereditary breast and ovarian cancer susceptibility genes (Review). Oncol Rep [Internet]. 2013 Sep;30(3):1019–29. 9. Torres-Mejia G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Martinez-Matsushita L, et al. Recurrent BRCA1 and BRCA2 Mutations in Mexican Women with Breast Cancer. Cancer Epidemiol Biomarkers Prev [Internet]. 2015 Mar 1;24(3):498–505.  10. Orozco-Quiyono M, Cano-ColĂn S, Gorráez-De La Mora MT, Del M, Chima-Galán C, Saavedra-LladĂł D. CaracterĂsticas epidemiolĂłgicas del cáncer de mama y ovario hereditario y del cáncer de mama esporádico en una muestra de la poblaciĂłn del ISSSTE. Rev Esp MĂ©d Quir Vol. 2012;17(4):291–9. 11. Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. The Breast [Internet]. 2017 Feb;31:224–32. 12. Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer. Int J Clin Oncol [Internet]. 2017 Feb 28 [cited 2018 Sep 19];23(1):1–7. 13. Randall LM, Pothuri B. The genetic prediction of risk for gynecologic cancers. Gynecol Oncol [Internet]. 2016;141(1):10–6. 14. Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol [Internet]. 2016;140:565–74. 15. Vadaparampil ST. Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida. Clin Genet [Internet]. 2015;87:473–7.
